Terns Pharmaceuticals (Terns Pharmaceuticals) GF Value Rank : 0 (As of Jun. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals GF Value Rank?

Terns Pharmaceuticals has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Terns Pharmaceuticals GF Value Rank Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Terns Pharmaceuticals (Terns Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

430:Germany

Address

1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404

Website

https://www.ternspharma.com

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

Executives

Mark J. Vignola	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Seokho Bryan Yoon	officer: COO and General Counsel	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram	director, officer: Chief Executive Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Hongbo Lu	director	C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Lav Biosciences Fund V, L.p.	10 percent owner	C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Lav Aqua Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Hopewell Resources Holdings Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Oriental Spring Venture Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Capital Gp Vii Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Asia Gp Iii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629